



October 7, 2025

Kissei Pharmaceutical Co., Ltd.
(Code 4547, Tokyo Stock Exchange Prime Market)

Licensing Agreement for "Linzagolix" with Searchlight Pharma in Canada

Kissei Pharmaceutical Co., Ltd. (Head Office: Matsumoto City, Nagano Prefecture; Chairman and CEO: Mutsuo Kanzawa; "Kissei") announced that it has entered into an agreement with Searchlight Pharma, (Head Office: Canada; President: Mark Nawacki; "Searchlight") to license development and commercialization rights in Canada for the GnRH antagonist "Linzagolix", which was discovered by Kissei.

By executing this agreement, Searchlight will develop and commercialize Linzagolix in Canada. Kissei will receive an upfront payment, milestone payments based on the progress of the development conducted and royalty payments according to the sales of product by Searchlight.

Linzagolix is an orally administered GnRH (gonadotropin-releasing hormone) antagonist. Linzagolix acts by antagonizing GnRH at the GnRH receptor in the pituitary gland and consequently suppressing the secretion of gonadotropins. Ultimately reducing the production of estrogen in the ovaries, it is expected to improve the symptoms of uterine fibroids and endometriosis.

In Japan, Kissei submitted a new drug application for the indication of uterine fibroids and is currently under regulatory review¹. Kissei is concurrently conducting a Phase III clinical trial for endometriosis². In overseas, Theramex (UK) launched the product under the brand name "Yselty®" for the indication of uterine fibroids in Europe in September 2024³. Furthermore, in November of the same year, Theramex received approval from the European Medicines Agency (EMA) for the additional indication of endometriosis⁴. Subsequently, Theramex has been progressing with the launch of the product across various European countries. In Taiwan, Synmosa Biopharmaceuticals (Taiwan) has filed for approval, and in South Korea, JW Pharma (Korea) is currently developing the drug.

Kissei is committed to the research and development of new drugs and strives to contribute to the health of people worldwide through collaboration with our partner companies.

The upfront payment arising from this transaction has been incorporated into the consolidated financial forecast for the fiscal year ending March 31, 2026, which was announced on May 7, 2025.

1 News Release: February 26, 2025

Submission of New Drug Application for GnRH Antagonist "Linzagolix" Indicated for Uterine Fibroids, in Japan

2 News Release: March 31, 2025

Kissei Initiates Phase III Clinical Trial for GnRH Antagonist "Linzagolix" Indicated for Endometriosis

3 Press Release: September 17, 2024

Launch of Yselty® (generic name linzagolix) for uterine fibroid treatment in Europe

4 News Release: December 23, 2024

Regarding the approval of the additional indication for endometriosis in Europe for the GnRH antagonist Yselty® (generic name linzagolix)

<Reference>

About Searchlight Pharma

Searchlight Pharma, Apotex's branded medicine division, executes best-in-class search, acquisition, and focused development of innovative and unique specialty healthcare products, with a core of its promoted products focused on women's health, dermatology, allergy, pain management and hospital specialty markets.

Apotex is a Canadian-based global health company. We improve everyday access to innovative medicines and health products for millions of people around the world, with a broad portfolio of generic, biosimilar, and innovative branded pharmaceuticals, and consumer health products. Headquartered in Toronto, with regional offices globally, including in the United States, Mexico, and India, we are the largest Canadian-based pharmaceutical company and a health partner of choice for the Americas for pharmaceutical licensing and product acquisitions.

Learn more about us at www.apotex.com and at www.searchlightpharma.com.